Back to results
US 2025/0026714 A1Published application
METHODS OF USING RARy AGONISTS FOR CANCER TREATMENT
AssigneeIo Therapeutics, Inc.
InventorsMartin E. Sanders, Vidyasagar Vuligonda
Life of this patent
Estimating the term…
Abstract
The invention discloses novel RAR gamma selective agonists used in the treatment of cancer. The invention also discloses administration of RAR gamma selective agonists to mammals, including humans for the purpose of selectively activating RAR gamma receptor and treat cancer by way of activating tumor infiltrating lymphocytes.
Claims13
A RARγ-selective agonist of the structure:
- or a pharmaceutically acceptable salt thereof, wherein R is H or C1-6 alkyl, and the crossed double bond to the ═N—OH group indicates that stereochemistry is not specified.
A RARγ-selective agonist of the structure:
- or a pharmaceutically acceptable salt thereof, wherein R is H or C1-6 alkyl;
- each R1 and R2 are independently H or C1-6 alkyl;
- R3 and R3′ are independently H, or halogen;
- (R4)2 comprises R4 and R4′ which are independently H, halogen, C1-6 alkyl or C1-6 alkoxy;
- X is O, S, CH2, C(R5)2, or NR6, wherein each R5 and R6 are independently H or C1-6 alkyl;
- the crossed double bond to the ═N—OH group indicates that stereochemistry is not specified;
- and the COOR group is in the meta or para position relative to the position of the linkage to the alkenyl group, and the two R4 groups occupy the remaining positions on the ring.
4 more elements
Dependencies are inferred from the claim text.